doi: 10.1177/096032718800700308.
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa
Affiliations
- PMID:3391625
- DOI: 10.1177/096032718800700308
Item in Clipboard
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa
D K Sommers et al. Hum Toxicol.1988 May.
Display options
Format
Display options
Format
Abstract
1. The metabolic oxidation of debrisoquine has been studied in a group of 96 San Bushmen. 2. The amounts of debrisoquine and 4-hydroxy-debrisoquine excreted in 0-8 h urine were measured and the metabolic ratio (% dose as debrisoquine/% dose as 4-hydroxy-debrisoquine) calculated. 3. On the basis of Caucasian criteria, that metabolic ratios greater than 12.6 represent poor metabolizers, 19% of the Bushmen were poor metabolizers in contrast to the 8-10% found in Caucasian studies. 4. Probit plots showed four modes may be present in the data, which may represent at least three isozymes of the relevant enzyme which may also differ from the Caucasian isozymes.
Similar articles
- Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.Sommers DK, Moncrieff J, Avenant J.Sommers DK, et al.Hum Toxicol. 1989 Jan;8(1):39-43. doi: 10.1177/096032718900800107.Hum Toxicol. 1989.PMID:2714809
- Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.Sommers DK, Moncrieff J, Avenant J.Sommers DK, et al.Hum Toxicol. 1989 Sep;8(5):365-8. doi: 10.1177/096032718900800506.Hum Toxicol. 1989.PMID:2807305
- Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.Du YL, Lou YQ.Du YL, et al.Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):7-10.Zhongguo Yao Li Xue Bao. 1990.PMID:2403020
- The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.Meyer UA, Skoda RC, Zanger UM.Meyer UA, et al.Pharmacol Ther. 1990;46(2):297-308. doi: 10.1016/0163-7258(90)90096-k.Pharmacol Ther. 1990.PMID:2181495Review.
- The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Lennard MS, Tucker GT, Woods HF.Lennard MS, et al.Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.Clin Pharmacokinet. 1986.PMID:2868819Review.
Cited by
- Dextromethorphan O-demethylation polymorphism in Jordanians.Irshaid YM, al-Hadidi HF, Rawashdeh NM.Irshaid YM, et al.Eur J Clin Pharmacol. 1993;45(3):271-3. doi: 10.1007/BF00315395.Eur J Clin Pharmacol. 1993.PMID:8276053
- Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.Dodgen TM, Labuschagne CJ, van Schalkwyk A, Steffens FE, Gaedigk A, Cromarty AD, Alessandrini M, Pepper MS.Dodgen TM, et al.Pharmacogenomics J. 2016 Nov;16(6):566-572. doi: 10.1038/tpj.2015.76. Epub 2015 Oct 27.Pharmacogenomics J. 2016.PMID:26503815
- Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama.Jorge LF, Arias TD, Inaba T, Jackson PR.Jorge LF, et al.Br J Clin Pharmacol. 1990 Aug;30(2):281-5. doi: 10.1111/j.1365-2125.1990.tb03776.x.Br J Clin Pharmacol. 1990.PMID:2206790Free PMC article.
- African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.Rajman I, Knapp L, Morgan T, Masimirembwa C.Rajman I, et al.EBioMedicine. 2017 Mar;17:67-74. doi: 10.1016/j.ebiom.2017.02.017. Epub 2017 Feb 20.EBioMedicine. 2017.PMID:28237373Free PMC article.
- Oxidative polymorphism of dextromethorphan in a Burundi population.Nsabiyumva F, Furet Y, Autret E, Jonville AP, Breteau M.Nsabiyumva F, et al.Eur J Clin Pharmacol. 1991;41(1):75-7. doi: 10.1007/BF00280112.Eur J Clin Pharmacol. 1991.PMID:1782983
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources